Lasya Lanterna
Now you can “Live in Your Best Light,” as Lasya, Incorporated announces the launch of its first product, Lanterna, a cosmetic cream containing 3% deoxyArbutin (dA). dA, originally developed by Lasya CEO Mitchell de Long, has been found to be highly effective in reducing the appearance of age spots, freckles, and other skin imperfections, and also improves the appearance of overall skin tone in as little as four weeks, with increased improvement in appearance with continued use.
In the most common laboratory test used to detect improvement in the appearance of skin pigmentation, dA was found to be thirty times more potent than Arbutin, a common cosmetic ingredient used to improve the appearance of skin tone. Additionally, unlike other popular compounds for similar use, which can rapidly degrade into harmful byproducts, deoxyArbutin has been shown to be stable to oxidation. “Given the exceptional characteristics of dA, including its safety and efficacy profile, it should rapidly displace many competitive products to become the most used compound for achieving the long sought goal of more even, more beautiful appearing skin,” stated de Long.
Lanterna will be marketed through dermatology practices, as well as on the company website, www.Lasyainc.com . A partnership with a national department store/cosmetic retailer is currently being sought. The MSRP for a one month supply is $94.50, with volume discounts for medical professionals. Product will begin shipping January 15, 2012.
Requests for additional information, wholesale inquiries, and professional sales can be directed to Amanda Greatens, Chief of Sales and Marketing, AmandaGreatens@Lasyainc.com, or via the company website, www.Lasyainc.com.
Lasya’s namesake is Lasya, the Tibetan Goddess of Beauty and Dignity of the Body. She is traditionally depicted wearing white clothing and carrying a mirror, and obtains her power from the light of the sun and of the moon.
See Also:
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
Comments
No comments yet.
Leave a comment